Daré Bioscience (DARE) Corporate presentation summary

Strategic focus and market opportunity

• Dedicated to women's health with a portfolio targeting large, underserved markets including sexual health, menopause, contraception, and HPV-related conditions.

• Over $75 million in non-dilutive funding from Gates Foundation, ARPA-H, and NIH supports development and validates the approach.

• Women's health represents a significant market, with millions affected by sexual arousal disorder, menopause, contraception needs, and HPV.

• 27% of blockbuster drugs are women's health products, and women make 80% of U.S. healthcare purchasing decisions.

Product pipeline and clinical progress

• Commercial launch of Flora Sync LF5 probiotic (June 2026) and DARE to PLAY Sildenafil Cream (Q3 2026) marks transition to revenue generation.

• Ovaprene, a hormone-free monthly contraceptive, is in Phase 3 with topline data expected in 2027.

• DARE-HPV, an antiviral vaginal insert for persistent high-risk HPV, is in Phase 2 with $10M in funding.

• DARE-HRT1 (menopause hormone therapy IVR) and DARE-VVA1 (hormone-free GSM therapy) are advancing with proprietary delivery systems.

• Additional pipeline assets address pelvic pain, long-acting contraception, and preterm birth.

Commercial strategy and infrastructure

• Integrated commercial platform includes DARE Health Hub, telehealth, and provider relationships for scalable growth.

• Strategic collaboration with MyMenopauseRx expands digital reach and patient access.

• Direct-to-patient model leverages digital marketing, influencer partnerships, and media to drive awareness and engagement.

• Provider engagement built through years of clinical development and presence at major women's health conferences.